Analyzing COLLPLANT HOLDI/S (CLGN) and Its Rivals

COLLPLANT HOLDI/S (NASDAQ: CLGN) is one of 27 public companies in the “Surgical appliances & supplies” industry, but how does it contrast to its rivals? We will compare COLLPLANT HOLDI/S to similar businesses based on the strength of its risk, institutional ownership, valuation, analyst recommendations, earnings, profitability and dividends.

Institutional & Insider Ownership

58.0% of shares of all “Surgical appliances & supplies” companies are owned by institutional investors. 10.3% of shares of all “Surgical appliances & supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for COLLPLANT HOLDI/S and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
COLLPLANT HOLDI/S 0 0 0 0 N/A
COLLPLANT HOLDI/S Competitors 175 823 1452 73 2.56

As a group, “Surgical appliances & supplies” companies have a potential upside of 18.77%. Given COLLPLANT HOLDI/S’s rivals higher possible upside, analysts plainly believe COLLPLANT HOLDI/S has less favorable growth aspects than its rivals.

Profitability

This table compares COLLPLANT HOLDI/S and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
COLLPLANT HOLDI/S -552.97% -80.17% -41.81%
COLLPLANT HOLDI/S Competitors -154.96% -220.52% -23.54%

Valuation & Earnings

This table compares COLLPLANT HOLDI/S and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
COLLPLANT HOLDI/S $480,000.00 -$6.02 million -2.49
COLLPLANT HOLDI/S Competitors $1.39 billion $210.14 million 21.35

COLLPLANT HOLDI/S’s rivals have higher revenue and earnings than COLLPLANT HOLDI/S. COLLPLANT HOLDI/S is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

COLLPLANT HOLDI/S rivals beat COLLPLANT HOLDI/S on 8 of the 9 factors compared.

COLLPLANT HOLDI/S Company Profile

CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. and is headquartered in Ness Ziona, Israel.

Receive News & Ratings for COLLPLANT HOLDI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COLLPLANT HOLDI/S and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply